[go: up one dir, main page]

MX2014001623A - Uso de la cardiotofina-1 para el tratamiento de enfermedades renales. - Google Patents

Uso de la cardiotofina-1 para el tratamiento de enfermedades renales.

Info

Publication number
MX2014001623A
MX2014001623A MX2014001623A MX2014001623A MX2014001623A MX 2014001623 A MX2014001623 A MX 2014001623A MX 2014001623 A MX2014001623 A MX 2014001623A MX 2014001623 A MX2014001623 A MX 2014001623A MX 2014001623 A MX2014001623 A MX 2014001623A
Authority
MX
Mexico
Prior art keywords
cardiotrophin
agents
treatment
kidney diseases
nephrotoxic
Prior art date
Application number
MX2014001623A
Other languages
English (en)
Inventor
Begoña García Cenador
Javier García Criado
Francisco Javier López Hernández
Jose Miguel López Novoa
María Pilar Perez De Obanos Martell
Juan Ruiz Echeverría
Original Assignee
Digna Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digna Biotech Sl filed Critical Digna Biotech Sl
Publication of MX2014001623A publication Critical patent/MX2014001623A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con el uso de cardiotrofina-1 (CT-1) para la prevención y/o el tratamiento del daño renal agudo, especialmente del daño renal agudo inducido por agentes nefrotóxicos, tales como agentes de contraste, antibióticos, agentes inmunosupresores o agentes antineoplásicos. La invención también contempla composiciones que comprenden dichos agentes nefrotóxicos y cardiotrofina-1.
MX2014001623A 2011-08-10 2012-08-10 Uso de la cardiotofina-1 para el tratamiento de enfermedades renales. MX2014001623A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201100933 2011-08-10
PCT/ES2012/070624 WO2013021093A1 (es) 2011-08-10 2012-08-10 Uso de la cardiotofina-1 para el tratamiento de enfermedades renales

Publications (1)

Publication Number Publication Date
MX2014001623A true MX2014001623A (es) 2015-03-09

Family

ID=47016719

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001623A MX2014001623A (es) 2011-08-10 2012-08-10 Uso de la cardiotofina-1 para el tratamiento de enfermedades renales.

Country Status (9)

Country Link
US (1) US20140170125A1 (es)
EP (1) EP2742948A1 (es)
JP (1) JP2014522879A (es)
CN (1) CN103857407A (es)
AU (1) AU2012293574A1 (es)
BR (1) BR112014003118A2 (es)
CA (1) CA2844792A1 (es)
MX (1) MX2014001623A (es)
WO (1) WO2013021093A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2967499C (en) * 2014-11-12 2023-01-17 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
CN105963716A (zh) * 2016-06-30 2016-09-28 广东省人民医院 碘对比剂诱导急性肾损伤动物模型建立方法
WO2018220224A1 (en) 2017-06-02 2018-12-06 Medirista Biotechnologies Ab Lipid-related antigens and antibodies directed against them
IT201900007446A1 (it) * 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
CN110260799B (zh) * 2019-07-29 2024-07-23 海伯森技术（深圳）有限公司 一种光谱共焦位移传感器
CA3152922A1 (en) * 2019-10-12 2021-04-15 Michael Peel Treatment and prevention of nephrotoxin-induced kidney injuries

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2511870A1 (fr) 1981-08-28 1983-03-04 Guerbet Sa Procede pour augmenter la tolerance des produits opacifiants, composes utilisables a cet effet et produits opacifiants les contenant
FR2511871A1 (fr) 1981-08-28 1983-03-04 Guerbet Sa Procede pour augmenter la tolerance des produits opacifiants et produits opacifiants ainsi obtenus
FR2512014A1 (fr) 1981-08-28 1983-03-04 Guerbet Sa Composes bromes utilisables dans des produits opacifiants
FR2541272A1 (fr) 1983-02-23 1984-08-24 Guerbet Sa Composes bromes et produits opacifiants en contenant
US5256394A (en) 1991-10-23 1993-10-26 Boron Biologicals, Inc. Radiological imaging method, and contrast media reagents therefor
FR2736051B3 (fr) 1995-06-29 1997-09-26 Guerbet Sa Complexes metalliques de polyaminoacides, leur procede de preparation et leur utilisation en imagerie diagnostique
US6423681B1 (en) 1999-05-04 2002-07-23 The Trustees Of Columbia University In The City Of New York Method of inducing formation of kidney epithelia from mesenchymal precursors
EP1186305A1 (en) 2000-09-07 2002-03-13 Schering Aktiengesellschaft New brominated compounds as contrast media for X-ray mammography
JP5266460B2 (ja) * 2005-06-16 2013-08-21 ハダジット メディカル リサーチ サービシズ アンド ディベラップメント リミテッド 腎不全を治療するための方法
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
WO2009108695A2 (en) * 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury
AU2011257148A1 (en) * 2010-05-24 2013-01-10 Digna Biotech, S.L. Composition for the cold storage of organs

Also Published As

Publication number Publication date
CA2844792A1 (en) 2013-02-14
US20140170125A1 (en) 2014-06-19
BR112014003118A2 (pt) 2017-03-14
AU2012293574A1 (en) 2014-03-06
WO2013021093A1 (es) 2013-02-14
CN103857407A (zh) 2014-06-11
JP2014522879A (ja) 2014-09-08
EP2742948A1 (en) 2014-06-18

Similar Documents

Publication Publication Date Title
CA2871471C (en) Dna-pk inhibitors
EA201390274A1 (ru) Борсодержащие малые молекулы
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
WO2013122888A3 (en) Methods of treating bacterial infections
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
PH12013502686A1 (en) Pesticidal compositions and processes related thereto
IN2014DN10670A (es)
MX346602B (es) Compuestos beta-lactamicos sustituidos con amidina, su preparacion y uso como agentes antibacterianos.
EP4414376A3 (en) Novel depsipeptide and uses thereof
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
WO2013070615A8 (en) Combination therapies using anti- pseudomonas psl and pcrv binding molecules
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
PH12013501654A1 (en) Pesticidal compositions and processes related thereto
EA201290642A1 (ru) Соединения и способы
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
GEP201706656B (en) 2-thiopyrimidinones
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
EA201391399A1 (ru) Макроциклическое соединение и способы его получения
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
IN2014CN00572A (es)
SG10201900541QA (en) Derivatives of xanthone compounds
GEP201606595B (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) –nifuratel
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.